To include your compound in the COVID-19 Resource Center, submit it here.

Following JV, Sino backs Akeso's $150M series D

Six months after establishing a joint venture with Akeso, Sino Biopharmaceutical has co-led a series D round of about $150 million in the Zhongshan-based cancer and autoimmune

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE